A randomized clinical trial of an antiplatelet agent in the treatment of acute stroke: cilostazol in the prevention of acute progressing stroke (CAPS) study
Phase 4
Recruiting
- Conditions
- Cerebral infarction
- Registration Number
- JPRN-UMIN000001630
- Lead Sponsor
- Tohoku Acute Progressing Stroke Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
Not provided
Exclusion Criteria
1) mRS before the onset > or = 2 2) NIHSS score > or = 20 3) Remarkably unstable symptom (measurement of NIHSS difficult) 4) Patients who should be treated with alteplase or other thrombolytic therapies 5) Patients who should be treated with reconstructive surgery (bypass or endovascular treatment) 6) Severe swallowing disturbance 7) Serious systemic complications (carcinoma,liver cirrhosis,renal failure, heart failure, etc.) 8) Contraindications to cilostazol 9) Patients who are considered unsuitable for inclusion in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method